All Major Solid Tumors

Cancer Type

Tumor Tissue (FFPE)

Sample Type

10 Working Days

Turnaround Time ¹

ACTFusion™ is a targeted, multi-biomarker assay that examines 13 druggable fusion genes, and more than 350 known and novel transcripts.

Precision Medicine to Plan Better Treatment

Precision Medicine to Plan Better Treatment

Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling can identify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.

Learn More

Why ACT Genomics?

Humane Process

Avoids multiple biopsies and the time cost associated with single-gene testing, as only a small specimen is required for the simultaneous detection of various fusion genes.

Ideal Treatment

Nominates proper targeted options.

Smart Budgeting

Evaluates options before treatment, according to genomic information, to ensure success rate and avoid wasting of funds.

Learn More

What Are Your Chances for Significant Tumor Shrinkage?

The chances of tumor shrinking with targeted therapy increase when something is found at which to aim. In addition to the common genomic alterations, such as a point mutation, insertion and deletion, a fusion gene, which is formed by chromosomal translocation, is newly identified as a target for tumor growth. The fusion gene is known to be complicated, includes hundreds of transcripts and is found in a wide range of cancer types to differing degrees. The highest prevelance of fusion genes are 15% in thyroid cancer and 10% in non-small cell lung cancer. For patients with fusion genes across cancer types, the good news is that the first tumor agnostic treatment has shown significant tumor shrinkage in 17 cancer types for patients with NTRK1/2/3 fusion, and it also works on ALK and ROS1 fusions. This tumor agnostic treatment was approved by the US FDA in 2018. For patients with RET, MET, NRG1 fusion, more global clinical trials await registration.

fusion genes

Common Problems in Cancer Treatment

  • Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
  • Complications and metastases make it difficult to determine an appropriate drug
  • Ineffective treatment and cancer relapse after targeted therapy

Diagnostic Solutions for Various Cancers

Through next-generation sequencing (NGS), ACTFusion™ fusion gene testing decodes 13 fusion genes and more than 350 transcripts to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate.

ACTFusion™ is suitable for breast, lung, colon cancers and other solid tumors. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Who Is Suitable for ACTFusion™?

  • All major solid tumors
  • Newly diagnosed, advanced, recurrent, and metastatic cancer


No items found.

Disclaimers / Footnotes

  1. Turnaround time starts from the date of receipt of approved samples at our CAP-accredited laboratory.

Book a Test

Explore the immense possibilities and promising future of precision medicine. Together, let us unlock the power of genomic testing and personalize cancer care for the most effective treatment.

Get Started